The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia

Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (A...

Full description

Saved in:
Bibliographic Details
Published inBlood research Vol. 53; no. 3; pp. 198 - 204
Main Authors Park, Yumi, Lim, Jinsook, Kim, Seonyoung, Song, Ikchan, Kwon, Kyechul, Koo, Sunhoe, Kim, Jimyung
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 01.09.2018
대한혈액학회
Subjects
Online AccessGet full text
ISSN2287-979X
2288-0011
DOI10.5045/br.2018.53.3.198

Cover

Abstract Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML). Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed. The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission ( =0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities ( =0.0244) and relapse ( =0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival. Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.
AbstractList Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).BACKGROUNDTumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.METHODSLymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.RESULTSThe percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.CONCLUSIONLymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.
Background Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lym-phocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML). Methods Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed. Results The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent pre-dictors of survival. Conclusion Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival. KCI Citation Count: 1
Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML). Lymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed. The percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission ( =0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities ( =0.0244) and relapse ( =0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival. Lymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.
Author Kim, Seonyoung
Park, Yumi
Lim, Jinsook
Song, Ikchan
Kwon, Kyechul
Koo, Sunhoe
Kim, Jimyung
AuthorAffiliation 2 Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea
1 Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
AuthorAffiliation_xml – name: 1 Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– name: 2 Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea
Author_xml – sequence: 1
  givenname: Yumi
  surname: Park
  fullname: Park, Yumi
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– sequence: 2
  givenname: Jinsook
  surname: Lim
  fullname: Lim, Jinsook
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– sequence: 3
  givenname: Seonyoung
  surname: Kim
  fullname: Kim, Seonyoung
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– sequence: 4
  givenname: Ikchan
  surname: Song
  fullname: Song, Ikchan
  organization: Department of Hemato-Oncology, Chungnam National University Hospital, Daejeon, Korea
– sequence: 5
  givenname: Kyechul
  surname: Kwon
  fullname: Kwon, Kyechul
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– sequence: 6
  givenname: Sunhoe
  surname: Koo
  fullname: Koo, Sunhoe
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
– sequence: 7
  givenname: Jimyung
  surname: Kim
  fullname: Kim, Jimyung
  organization: Department of Laboratory Medicine, Chungnam National University Hospital, Daejeon, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30310785$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002385320$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp1kc1v1DAQxS1UREvpnRPyEQ4J_ojj-IJUVRQqVUJCW4mb5TiTrlknDnYCyn9f726LAAlfxpJ_773xzEt0MoYREHpNSSlIJd63sWSENqXgJS-pap6hM8aapiCE0pPDXRZKqm-n6CKl7ySfRkrFxAt0ygmnRDbiDN1ttoCnGO7HkGZnsRsmY2cceuzXYdoGu86A09ImmBN2Ix7hl19x58xeAB02dsnAsIIPrsMelh0MzrxCz3vjE1w81nN0d_1xc_W5uP3y6ebq8rawFSdzYRknrKlon1sF3nFWS2ANs31twdYt472wwliRf8QM5zy3rCrSg1XKykpafo7eHX3H2OuddToYd6j3Qe-ivvy6udFc1qypRWY_HNlpaQfoLIxzNF5P0Q0mrgfl3y-j22afn7qmMo-LZYO3jwYx_FggzXpwyYL3ZoSwJM0oVYqRulYZffNn1u-Qp7lnoD4CNoaUIvTautnMLuyjndeU6P2OdRv1fsdacM113nEWkn-ET97_lTwAFlip4g
CitedBy_id crossref_primary_10_1002_cyto_b_22197
crossref_primary_10_1007_s12308_023_00536_9
crossref_primary_10_1097_CEJ_0000000000000905
crossref_primary_10_1515_cclm_2021_0736
crossref_primary_10_3389_fcell_2021_800267
crossref_primary_10_5858_arpa_2023_0284_OA
crossref_primary_10_15264_cpho_2019_26_1_1
Cites_doi 10.4110/in.2014.14.6.289
10.1007/s00282-997-0301-3
10.1200/JCO.2003.04.036
10.3324/haematol.2013.087536
10.1038/sj.bjc.6601219
10.1038/cmi.2013.10
10.1007/BF01715050
10.4161/cbt.25938
10.1182/blood-2009-11-254441
10.1111/j.1365-2141.2008.07070.x
10.1038/sj.leu.2402835
10.1038/sj.leu.2403985
10.1182/blood-2016-03-643544
10.1038/sj.leu.2401452
10.3324/haematol.11702
10.1182/blood-2011-07-365817
10.3109/10428194.2015.1020060
10.1186/1479-5876-12-30
10.1111/ijlh.12594
10.1002/cyto.b.21349
10.1038/bjc.2011.189
10.1182/blood-2009-02-206946
10.1038/sj.leu.2400891
ContentType Journal Article
Copyright 2018 Korean Society of Hematology 2018 Korean Society of Hematology
Copyright_xml – notice: 2018 Korean Society of Hematology 2018 Korean Society of Hematology
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.5045/br.2018.53.3.198
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2288-0011
EndPage 204
ExternalDocumentID oai_kci_go_kr_ARTI_3762865
PMC6170312
30310785
10_5045_br_2018_53_3_198
Genre Journal Article
GroupedDBID 0R~
5-W
8JR
8XY
9ZL
AAJSJ
AAKKN
AASML
AAYXX
ABEEZ
ACACY
ACULB
ADBBV
ADRAZ
AFGXO
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
C24
C6C
CITATION
DIK
EBLON
EF.
FRP
HYE
KQ8
M48
PGMZT
RPM
SOJ
W2D
M~E
NPM
OK1
RSV
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c430t-c2302841f287e3d3267e282cf6cec6b23f5c5ac50012a333078940fec99c747c3
IEDL.DBID M48
ISSN 2287-979X
IngestDate Sun Jan 21 03:11:41 EST 2024
Thu Aug 21 13:57:30 EDT 2025
Fri Jul 11 01:32:45 EDT 2025
Wed Feb 19 02:43:44 EST 2025
Thu Apr 24 23:08:35 EDT 2025
Tue Jul 01 01:58:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords NK cells
Prognosis
Acute myeloid leukemia
Lymphocyte subset
Language English
License http://creativecommons.org/licenses/by-nc/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c430t-c2302841f287e3d3267e282cf6cec6b23f5c5ac50012a333078940fec99c747c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.5045/br.2018.53.3.198
PMID 30310785
PQID 2119920669
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_3762865
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6170312
proquest_miscellaneous_2119920669
pubmed_primary_30310785
crossref_citationtrail_10_5045_br_2018_53_3_198
crossref_primary_10_5045_br_2018_53_3_198
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-09-01
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Blood research
PublicationTitleAlternate Blood Res
PublicationYear 2018
Publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
대한혈액학회
Publisher_xml – name: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
– name: 대한혈액학회
References Le Dieu (10.5045/br.2018.53.3.198_ref9) 2009; 114
Cheng (10.5045/br.2018.53.3.198_ref4) 2013; 10
Stringaris (10.5045/br.2018.53.3.198_ref10) 2014; 99
Ustun (10.5045/br.2018.53.3.198_ref23) 2011; 118
Woo (10.5045/br.2018.53.3.198_ref5) 2014; 12
(10.5045/br.2018.53.3.198_ref1) 1992; 41
Tzankov (10.5045/br.2018.53.3.198_ref6) 2008; 93
Ohnishi (10.5045/br.2018.53.3.198_ref14) 1998; 12
Guo (10.5045/br.2018.53.3.198_ref24) 2013; 14
Alcasid (10.5045/br.2018.53.3.198_ref8) 2017; 39
Bruserud (10.5045/br.2018.53.3.198_ref12) 1999; 13
Palmer (10.5045/br.2018.53.3.198_ref21) 2008; 141
Bar (10.5045/br.2018.53.3.198_ref16) 2015; 56
Mociková (10.5045/br.2018.53.3.198_ref7) 2010; 111
Siegler (10.5045/br.2018.53.3.198_ref13) 2005; 19
Arber (10.5045/br.2018.53.3.198_ref17) 2016; 127
Cheson (10.5045/br.2018.53.3.198_ref19) 2003; 21
Gooden (10.5045/br.2018.53.3.198_ref3) 2011; 105
Grimwade (10.5045/br.2018.53.3.198_ref18) 2010; 116
Aggarwal (10.5045/br.2018.53.3.198_ref22) 2016; 90
Vidriales (10.5045/br.2018.53.3.198_ref11) 1993; 67
Adami (10.5045/br.2018.53.3.198_ref2) 2003; 89
Parrado (10.5045/br.2018.53.3.198_ref15) 1997; 39
Panoskaltsis (10.5045/br.2018.53.3.198_ref25) 2003; 17
Choi (10.5045/br.2018.53.3.198_ref20) 2014; 14
10450745 - Leukemia. 1999 Aug;13(8):1175-87
14520450 - Br J Cancer. 2003 Oct 6;89(7):1221-7
18384436 - Br J Haematol. 2008 May;141(5):607-14
9436920 - Leukemia. 1998 Jan;12(1):52-8
24488563 - Haematologica. 2014 May;99(5):836-47
28133918 - Int J Lab Hematol. 2017 Apr;39(2):129-136
24475900 - J Transl Med. 2014 Jan 30;12:30
24030391 - Cancer Biol Ther. 2013 Oct 1;14(10):916-21
16224486 - Leukemia. 2005 Dec;19(12):2215-22
25726954 - Leuk Lymphoma. 2015;56(11):3109-15
18223287 - Haematologica. 2008 Feb;93(2):193-200
23604045 - Cell Mol Immunol. 2013 May;10(3):230-52
19710498 - Blood. 2009 Oct 29;114(18):3909-16
20359433 - Prague Med Rep. 2010;111(1):5-11
7694663 - Ann Hematol. 1993 Nov;67(5):217-22
1361652 - MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
20385793 - Blood. 2010 Jul 22;116(3):354-65
14673054 - J Clin Oncol. 2003 Dec 15;21(24):4642-9
26648320 - Cytometry B Clin Cytom. 2016 Jul;90(4):349-57
25550695 - Immune Netw. 2014 Dec;14(6):289-95
9497889 - Hematol Cell Ther. 1997 Dec;39(6):301-6
27069254 - Blood. 2016 May 19;127(20):2391-405
21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103
12682629 - Leukemia. 2003 Apr;17(4):716-30
21881045 - Blood. 2011 Nov 10;118(19):5084-95
References_xml – volume: 14
  start-page: 289
  year: 2014
  ident: 10.5045/br.2018.53.3.198_ref20
  publication-title: Immune Netw
  doi: 10.4110/in.2014.14.6.289
– volume: 39
  start-page: 301
  year: 1997
  ident: 10.5045/br.2018.53.3.198_ref15
  publication-title: Hematol Cell Ther
  doi: 10.1007/s00282-997-0301-3
– volume: 21
  start-page: 4642
  year: 2003
  ident: 10.5045/br.2018.53.3.198_ref19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.04.036
– volume: 99
  start-page: 836
  year: 2014
  ident: 10.5045/br.2018.53.3.198_ref10
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.087536
– volume: 41
  start-page: 1
  year: 1992
  ident: 10.5045/br.2018.53.3.198_ref1
  publication-title: MMWR Recomm Rep
– volume: 89
  start-page: 1221
  year: 2003
  ident: 10.5045/br.2018.53.3.198_ref2
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601219
– volume: 10
  start-page: 230
  year: 2013
  ident: 10.5045/br.2018.53.3.198_ref4
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2013.10
– volume: 67
  start-page: 217
  year: 1993
  ident: 10.5045/br.2018.53.3.198_ref11
  publication-title: Ann Hematol
  doi: 10.1007/BF01715050
– volume: 14
  start-page: 916
  year: 2013
  ident: 10.5045/br.2018.53.3.198_ref24
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.25938
– volume: 116
  start-page: 354
  year: 2010
  ident: 10.5045/br.2018.53.3.198_ref18
  publication-title: Blood
  doi: 10.1182/blood-2009-11-254441
– volume: 141
  start-page: 607
  year: 2008
  ident: 10.5045/br.2018.53.3.198_ref21
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2008.07070.x
– volume: 17
  start-page: 716
  year: 2003
  ident: 10.5045/br.2018.53.3.198_ref25
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2402835
– volume: 19
  start-page: 2215
  year: 2005
  ident: 10.5045/br.2018.53.3.198_ref13
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403985
– volume: 111
  start-page: 5
  year: 2010
  ident: 10.5045/br.2018.53.3.198_ref7
  publication-title: Prague Med Rep
– volume: 127
  start-page: 2391
  year: 2016
  ident: 10.5045/br.2018.53.3.198_ref17
  publication-title: Blood
  doi: 10.1182/blood-2016-03-643544
– volume: 13
  start-page: 1175
  year: 1999
  ident: 10.5045/br.2018.53.3.198_ref12
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401452
– volume: 93
  start-page: 193
  year: 2008
  ident: 10.5045/br.2018.53.3.198_ref6
  publication-title: Haematologica
  doi: 10.3324/haematol.11702
– volume: 118
  start-page: 5084
  year: 2011
  ident: 10.5045/br.2018.53.3.198_ref23
  publication-title: Blood
  doi: 10.1182/blood-2011-07-365817
– volume: 56
  start-page: 3109
  year: 2015
  ident: 10.5045/br.2018.53.3.198_ref16
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2015.1020060
– volume: 12
  start-page: 30
  year: 2014
  ident: 10.5045/br.2018.53.3.198_ref5
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-12-30
– volume: 39
  start-page: 129
  year: 2017
  ident: 10.5045/br.2018.53.3.198_ref8
  publication-title: Int J Lab Hematol
  doi: 10.1111/ijlh.12594
– volume: 90
  start-page: 349
  year: 2016
  ident: 10.5045/br.2018.53.3.198_ref22
  publication-title: Cytometry B Clin Cytom
  doi: 10.1002/cyto.b.21349
– volume: 105
  start-page: 93
  year: 2011
  ident: 10.5045/br.2018.53.3.198_ref3
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.189
– volume: 114
  start-page: 3909
  year: 2009
  ident: 10.5045/br.2018.53.3.198_ref9
  publication-title: Blood
  doi: 10.1182/blood-2009-02-206946
– volume: 12
  start-page: 52
  year: 1998
  ident: 10.5045/br.2018.53.3.198_ref14
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2400891
– reference: 14520450 - Br J Cancer. 2003 Oct 6;89(7):1221-7
– reference: 18223287 - Haematologica. 2008 Feb;93(2):193-200
– reference: 21881045 - Blood. 2011 Nov 10;118(19):5084-95
– reference: 27069254 - Blood. 2016 May 19;127(20):2391-405
– reference: 24030391 - Cancer Biol Ther. 2013 Oct 1;14(10):916-21
– reference: 24475900 - J Transl Med. 2014 Jan 30;12:30
– reference: 25550695 - Immune Netw. 2014 Dec;14(6):289-95
– reference: 28133918 - Int J Lab Hematol. 2017 Apr;39(2):129-136
– reference: 7694663 - Ann Hematol. 1993 Nov;67(5):217-22
– reference: 10450745 - Leukemia. 1999 Aug;13(8):1175-87
– reference: 18384436 - Br J Haematol. 2008 May;141(5):607-14
– reference: 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103
– reference: 24488563 - Haematologica. 2014 May;99(5):836-47
– reference: 12682629 - Leukemia. 2003 Apr;17(4):716-30
– reference: 19710498 - Blood. 2009 Oct 29;114(18):3909-16
– reference: 9497889 - Hematol Cell Ther. 1997 Dec;39(6):301-6
– reference: 26648320 - Cytometry B Clin Cytom. 2016 Jul;90(4):349-57
– reference: 16224486 - Leukemia. 2005 Dec;19(12):2215-22
– reference: 23604045 - Cell Mol Immunol. 2013 May;10(3):230-52
– reference: 25726954 - Leuk Lymphoma. 2015;56(11):3109-15
– reference: 20385793 - Blood. 2010 Jul 22;116(3):354-65
– reference: 20359433 - Prague Med Rep. 2010;111(1):5-11
– reference: 1361652 - MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
– reference: 9436920 - Leukemia. 1998 Jan;12(1):52-8
– reference: 14673054 - J Clin Oncol. 2003 Dec 15;21(24):4642-9
SSID ssj0000877925
Score 2.140705
Snippet Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether...
Background Tumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 198
SubjectTerms Original
병리학
Title The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/30310785
https://www.proquest.com/docview/2119920669
https://pubmed.ncbi.nlm.nih.gov/PMC6170312
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002385320
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Blood Research, 2018, 53(3), , pp.198-204
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj9MwELbYRUJcVizP8lgZxIVDsmknj-aEENrVglROVOrNssc2RM0mbJpK5N8zk2QLRRXilEPsWJmxPd_nsT8L8Tb2vNRITFWD9UE8jW2gs8gEgAYpWoPWjjO6iy_p1TL-vEpWv49HjwbcHKR2fJ_UsinDnzfdexrwhF_DhBDJuWFdz-k8TCCEkEj0kbhLcSllKrYYwX4_L8-zLO9vYZ0RTQjyLF8NecuDH9mLU0dV4w9B0L93Uv4Rmi4fiJMRU8oPQyc4FXdc9VDcW4xZ80diSX1B8kasqmZVZjmcjJS1l2VHzqyxa53c0Azi2o0sKklIu-ykHTbhOSs1bqnAdefKurCydNu1uy70Y7G8vPj68SoYr1MIMIaoDZCcQsFo6unvHVjCbZkjwoU-RYepmYFPMNGYMALSAMBC9HHkHeY5EulAeCKOq7pyz4S0fmZsBJCaFOM0wrkz1rL2F_UHm_h4Is5vjadw1BrnKy9KRZyDza1Mo9jcKgEFisw9Ee92NX4MOhv_KPuG_KHWWCgWx-bnt1qtG0UU4JOiGZNP207E61t3KRoxnAbRlau3G8Wadjmr2OcT8XRw365JYKXUbE61sz3H7gpwg_tvquJ7r8rNyvYwnT3_j3ZfiPv8Q8NWtZfiuG227hVhm9ac9V32rF90-gU1n_fU
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prognostic+impact+of+lymphocyte+subsets+in+newly+diagnosed+acute+myeloid+leukemia&rft.jtitle=Blood+research&rft.au=Park%2C+Yumi&rft.au=Lim%2C+Jinsook&rft.au=Kim%2C+Seonyoung&rft.au=Song%2C+Ikchan&rft.date=2018-09-01&rft.issn=2287-979X&rft.volume=53&rft.issue=3&rft.spage=198&rft_id=info:doi/10.5045%2Fbr.2018.53.3.198&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-979X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-979X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-979X&client=summon